Nanobiotix (NASDAQ:NBTX – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.58) per share and revenue of $3.55 million for the quarter.
Nanobiotix Trading Down 4.0 %
NASDAQ:NBTX opened at $3.62 on Friday. The company has a fifty day moving average price of $3.51 and a 200 day moving average price of $3.90. Nanobiotix has a one year low of $2.76 and a one year high of $7.51.
Wall Street Analyst Weigh In
Separately, UBS Group upgraded shares of Nanobiotix to a “hold” rating in a research report on Monday, February 17th.
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
- Five stocks we like better than Nanobiotix
- How to Capture the Benefits of Dividend Increases
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
